%0 Journal Article
%A Martín, Miguel
%A Rodríguez-Lescure, Álvaro
%A Ruiz, Amparo
%A Alba Conejo, Emilio
%A Calvo, Lourdes
%A Ruiz-Borrego, Manuel
%A Muñárriz, Blanca
%A Rodríguez, César A
%A Crespo, Carmen
%A Álava, Enrique de
%A López García-Asenjo, José Antonio
%A Guitián, María Dolores
%A Almenar, Sergio
%A González-Palacios, Jesús Fernando
%A Vera, Francisco
%A Palacios, José
%A Ramos, Manuel
%A Gracia Marco, José Manuel
%A Lluch, Ana
%A Álvarez, Isabel
%A Seguí, Miguel Ángel
%A Mayordomo, José Ignacio
%A Antón, Antonio
%A Baena, José Manuel
%A Plazaola, Arrate
%A Modolell, Alfonso
%A Pelegrí, Amadeu
%A Mel, José Ramón
%A Aranda, Enrique
%A Adrover, Encarna
%A Valero Álvarez, José
%A García Puche, José Luis
%A Sánchez-Rovira, Pedro
%A González, Sonia
%A López-Vega, José Manuel
%T Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
%D 2008
%@ 0027-8874
%U http://hdl.handle.net/10668/749
%X BACKGROUNDTaxanes are among the most active drugs for the treatment of metastatic breast cancer, and, as a consequence, they have also been studied in the adjuvant setting.METHODSAfter breast cancer surgery, women with lymph node-positive disease were randomly assigned to treatment with fluorouracil, epirubicin, and cyclophosphamide (FEC) or with FEC followed by weekly paclitaxel (FEC-P). The primary endpoint of study-5-year disease-free survival (DFS)-was assessed by Kaplan-Meier analysis. Secondary endpoints included overall survival and analysis of the prognostic and predictive value of clinical and molecular (hormone receptors by immunohistochemistry and HER2 by fluorescence in situ hybridization) markers. Associations and interactions were assessed with a multivariable Cox proportional hazards model for DFS for the following covariates: age, menopausal status, tumor size, lymph node status, type of chemotherapy, tumor size, positive lymph nodes, HER2 status, and hormone receptor status. All statistical tests were two-sided.RESULTSAmong the 1246 eligible patients, estimated rates of DFS at 5 years were 78.5% in the FEC-P arm and 72.1% in the FEC arm (difference = 6.4%, 95% confidence interval [CI] = 1.6% to 11.2%; P = .006). FEC-P treatment was associated with a 23% reduction in the risk of relapse compared with FEC treatment (146 relapses in the 614 patients in the FEC-P arm vs 193 relapses in the 632 patients in the FEC arm, hazard ratio [HR] = 0.77, 95% CI = 0.62 to 0.95; P = .022) and a 22% reduction in the risk of death (73 and 95 deaths, respectively, HR = 0.78, 95% CI = 0.57 to 1.06; P = .110). Among the 928 patients for whom tumor samples were centrally analyzed, type of chemotherapy (FEC vs FEC-P) (P = .017), number of involved axillary lymph nodes (P < .001), tumor size (P = .020), hormone receptor status (P = .004), and HER2 status (P = .006) were all associated with DFS. We found no statistically significant interaction between HER2 status and paclitaxel treatment or between hormone receptor status and paclitaxel treatment.CONCLUSIONSAmong patients with operable breast cancer, FEC-P treatment statistically significantly reduced the risk of relapse compared with FEC as adjuvant therapy.
%K ERBB2 protein, human
%K Anciano
%K Antineoplásicos Fitogénicos
%K Protocolos de Quimioterapia Combinada Antineoplásica
%K Neoplasias de la Mama
%K Carcinoma Ductal de Mama
%K Carcinoma Lobular
%K Ciclofosfamida
%K Supervivencia sin Enfermedad
%K Esquema de Medicación
%K Epirrubicina
%K Fluorouracilo
%K Inmunohistoquímica
%K Hibridación Fluorescente In Situ
%K Infusiones Intravenosas
%K Estimación de Kaplan-Meier
%K Estadificación de Neoplasias
%K Pronóstico
%K Modelos de Riesgos Proporcionales
%K Receptor erbB-2
%K Receptores Estrogénicos
%K Receptores de Progesterona
%K Resultado del Tratamiento
%K Marcadores Biológicos de Tumor
%~